Novostella (Prasterone)

Prasterone is a precursor of both androgens and estrogens. After oral administration it is taken up by cells and converted by steroid‑converting enzymes into testosterone, dihydrotestosterone, and estradiol, thereby increasing the body’s natural sex‑steroid pool and correcting hormonal deficits.

The dosage of Novostella is individualized. A qualified prescriber determines the appropriate strength, frequency and duration based on the patient’s clinical condition, laboratory results and response to therapy. No fixed regimen is provided in public information.

Safety data for prasterone during pregnancy or lactation are limited. Because it can affect hormone levels, the product is generally not recommended for pregnant or nursing women unless the potential benefit justifies the potential risk and a specialist’s guidance is obtained.

To request Novostella, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Novostella delivers prasterone, a natural DHEA precursor, whereas many androgen products provide direct testosterone. Prasterone allows the body to balance both androgenic and estrogenic pathways, which can be advantageous for patients needing broader hormonal support, but individual response varies and should be evaluated by a clinician.

Novostella tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Novostella is taken orally, usually with water. The exact timing (e.g., with food or on an empty stomach) depends on the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without medical advice.

Serious adverse events associated with prasterone include hepatotoxicity (elevated liver enzymes or hepatitis), stimulation of hormone‑sensitive tumors such as prostate or breast cancer, and severe allergic reactions like anaphylaxis. Patients should report any signs of liver dysfunction, unusual swelling, or allergic symptoms promptly.

Novostella is contraindicated in individuals with known hypersensitivity to prasterone, active hormone‑dependent cancers (e.g., prostate or breast carcinoma), severe liver disease, or uncontrolled cardiovascular conditions. Caution is also advised for the elderly, pregnant or nursing women, and patients taking strong CYP3A4 inhibitors.